
Excited to share our new study describing uRARE-seq, a tumor-naive #LiquidBiopsy method for analyzing urine cell-free RNA (cfRNA) in #BladderCancer and other genitourinary cancers. Out today in @NatureMedicine 🧵 1/16 rdcu.be/bRoXk7REWtRa

cancer immunology - sarcoma - melanoma - radiation oncology - kalbasilab.org @stanford

Excited to share our new study describing uRARE-seq, a tumor-naive #LiquidBiopsy method for analyzing urine cell-free RNA (cfRNA) in #BladderCancer and other genitourinary cancers. Out today in @NatureMedicine 🧵 1/16 rdcu.be/bRoXk7REWtRa

How the hunt for human retroviruses led to the discovery of IL-2 and a path to immunotherapy science.org/doi/10.1126/scie…

Soft tissue sarcomas (#STS) have few recurrent mutations, making ctDNA testing a challenge. In our new paper in @JCO_ASCO, we show that personalized ctDNA analysis achieves high detection rates and can track treatment response in localized STS. 🧵 (1/11) doi.org/10.1200/JCO-26-00769

Way to go Kayla, so well-deserved!
Feeling incredibly thankful to be awarded an NIH F30 Fellowship to continue my PhD work in cancer immunology. And grateful for my PI @xrtcell and my amazing lab for their support!

Highly anticipated data with first in class modified TIL therapy that does not use IL2, has lower dose lymphodepleting chemo - single arm ph1/2 OBX-115 in refractory metastatic melanoma #ASCO26 @DrBetofMDPhD @StanfordCancer ORR 67% w 2 CR (!!) DoR not reached (1+ to 14+m)

SCI member @xrtcell & others show that combining targeted #RadiationTherapy with an experimental immune-boosting drug (BO-112) & anti-PD-1 therapy before surgery may help the immune system fight aggressive #SoftTissueSarcomas. brnw.ch/21x2SeG

🚨What if we could reliably program macrophage polarization state?🚨 biorxiv.org/content/10.64898… Macrophages are highly plastic immune cells that perform critical functions by polarizing into distinct cellular states. The polarization state of macrophages can substantially influences the progression of cancers, infections, and autoimmunity. (1/11)

If you haven’t REAP’d, have you really lived?
Autoantibodies cause autoimmune disease, shape infection outcomes, and alter cancer immunotherapy. But what role might they play in neuropsychiatric disease? In our new preprint, Katlyn Nemani and @JillianRJaycox take on this question in schizophrenia. 🧵 biorxiv.org/content/10.64898…

Made possible by Marisol Quintero & team @Highlight_HLT, @theNCI, @StanfordCancer, @ConquerCancerFd, @UCLAJCCC. And most importantly, our patients. /10

Congrats to first author @JieDeng (my first post-doc, now leading her own group), UCLA Sarcoma program, and our @StanfordMed team on rich correlatives (@AasthaPal @Stef_Tst @ZinaGood @aaronmring @everettmoding) /9

In a small ph1 (n=14) we cannot over-interpret outcomes. But scRNAseq shows BO-112+RT more effectively depletes malignant cells. LC and DFS (and ctDNA @EverettModing) in pts with high risk ext/trunk UPS/MFS were promising & support further clin dev (if tox is fully mitigated). /8

In longitudinal tumor specimens from pts we saw RT depletes T cells but not myeloid cells. BO-112 engages myeloid cells toward Ag presenting & IFN programs, driving clonal replacement with (less differentiated) T cells that form T cell:myeloid cell interacting doublets (Visium)/7

Seq data with empirical support suggests combo may induce T cell responses vs mesenchymal tumor Ags that cross-react with Ags in muscular tissues (sarcoma=mesenchymal). We safely re-introduced aPD1 in 4 patients (fewer doses of BO-112+aPD1). /6

The kicker: 2 of first 3 pts developed the same myositis-myocarditis-MG picture, an irAE observed rarely with aPD1 alone. We de-escalated and did not observe tox without aPD1. Also no tox with BO-112+aPD1 or aPD1+RT (other studies). Effect seems to require the triple combo. /5

In mice, intratumoral BO-112 and RT (tumor-only therapy) induces systemic T cell dependent anti-tumor immunity. BO-112 preferentially targets myeloid cells, which works out with RT, which depletes intratumoral lymphocytes but leaves intratumoral myeloid cells intact. /4

Note: we used hypofrac RT (6 Gy x 5; and no lymph nodes involved), in a regimen we have tested across multiple ph2 studies. /3